Want to see BOLT full AI Analyst Report?
Bolt Biotherapeutics (BOLT) Ratios
Bolt Biotherapeutics Ratios
BOLT's free cash flow for Q2 2026 was $-6.55M. For the 2026 fiscal year, BOLT's free cash flow was decreased by $-13.00K and operating cash flow was $-6.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.59 | 3.20 | 5.17 | 7.47 | 8.87 |
| Quick Ratio | 3.59 | 3.20 | 5.17 | 7.47 | 8.87 |
| Cash Ratio | 1.39 | 0.45 | 0.53 | 0.40 | 1.28 |
| Solvency Ratio | -1.06 | -1.45 | -1.43 | -1.54 | -1.69 |
| Operating Cash Flow Ratio | -4.72 | -3.87 | -3.40 | -3.31 | -2.68 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -22.82 |
| Net Current Asset Value | $ 17.00K | $ 8.38M | $ 58.66M | $ 116.44M | $ 131.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.25 | 0.13 | 0.10 | 0.08 |
| Debt-to-Equity Ratio | 0.87 | 0.44 | 0.18 | 0.13 | 0.10 |
| Debt-to-Capital Ratio | 0.46 | 0.31 | 0.15 | 0.12 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.14 | 1.74 | 1.42 | 1.33 | 1.23 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -36.62 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 12.28 | 0.66 | 0.53 | 0.61 | 0.65 |
| Net Debt to EBITDA | -0.35 | -0.27 | -0.13 | -0.15 | 0.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.62% | 100.00% | -681.39% | -1176.37% | -5904.37% |
| EBIT Margin | -433.74% | -887.33% | -967.45% | -1576.56% | -7364.13% |
| EBITDA Margin | -416.96% | -864.17% | -943.91% | -1547.48% | -7269.44% |
| Operating Profit Margin | -450.07% | -949.91% | -967.45% | -1576.56% | -7364.13% |
| Pretax Profit Margin | -433.74% | -820.78% | -878.58% | -1537.76% | -7824.68% |
| Net Profit Margin | -433.74% | -820.78% | -878.58% | -1537.76% | -7824.68% |
| Continuous Operations Profit Margin | -433.74% | -820.78% | -878.58% | -1537.76% | -7824.68% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.37% | 86.41% | 90.81% | 97.54% | 106.25% |
| Return on Assets (ROA) | -58.81% | -63.35% | -43.31% | -38.67% | -32.04% |
| Return on Equity (ROE) | -125.92% | -110.35% | -61.38% | -51.37% | -39.42% |
| Return on Capital Employed (ROCE) | -71.68% | -87.19% | -54.69% | -44.13% | -32.40% |
| Return on Invested Capital (ROIC) | -67.72% | -84.91% | -53.62% | -43.62% | -32.12% |
| Return on Tangible Assets | -58.81% | -63.35% | -43.31% | -38.67% | -32.04% |
| Earnings Yield | -326.30% | -15.45% | -8.17% | -9.07% | -2.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.91 | 6.60 | 0.00 | 0.00 | 6.30 |
| Payables Turnover | 1.03 | 0.00 | 20.60 | 20.35 | 21.17 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.38 | 0.31 | 0.33 | 0.20 | 0.04 |
| Asset Turnover | 0.14 | 0.08 | 0.05 | 0.03 | 0.00 |
| Working Capital Turnover Ratio | 0.27 | 0.13 | 0.07 | 0.04 | 0.01 |
| Cash Conversion Cycle | -307.10 | 55.30 | -17.72 | -17.94 | 40.69 |
| Days of Sales Outstanding | 46.15 | 55.30 | 0.00 | 0.00 | 57.94 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 353.25 | 0.00 | 17.72 | 17.94 | 17.24 |
| Operating Cycle | 46.15 | 55.30 | 0.00 | 0.00 | 57.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -21.31 | -1.61 | -1.84 | -2.05 | -1.53 |
| Free Cash Flow Per Share | -21.35 | -1.61 | -1.84 | -2.10 | -1.59 |
| Dividend Paid and CapEx Coverage Ratio | -553.47 | -1494.85 | -337.50 | -39.17 | -24.41 |
| Capital Expenditure Coverage Ratio | -553.47 | -1494.85 | -337.50 | -39.17 | -24.41 |
| Operating Cash Flow Coverage Ratio | -1.74 | -2.43 | -3.44 | -3.38 | -2.34 |
| Operating Cash Flow to Sales Ratio | -5.18 | -7.97 | -8.83 | -13.35 | -45.29 |
| Free Cash Flow Yield | -390.30% | -15.01% | -8.23% | -8.08% | -1.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.31 | -6.47 | -12.24 | -11.03 | -37.18 |
| Price-to-Sales (P/S) Ratio | 1.33 | 53.13 | 107.54 | 169.54 | 2908.87 |
| Price-to-Book (P/B) Ratio | 0.39 | 7.14 | 7.51 | 5.66 | 14.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.26 | -6.66 | -12.15 | -12.38 | -61.70 |
| Price-to-Operating Cash Flow Ratio | -0.26 | -6.67 | -12.18 | -12.70 | -64.23 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.66 | 0.60 | 0.63 | -0.92 |
| Enterprise Value Multiple | -0.67 | -6.42 | -11.52 | -11.11 | -39.98 |
| Enterprise Value | 21.48M | 426.57M | 856.40M | 984.69M | 3.66B |
| EV to EBITDA | -0.67 | -6.42 | -11.52 | -11.11 | -39.98 |
| EV to Sales | 2.79 | 55.47 | 108.74 | 171.88 | 2906.46 |
| EV to Free Cash Flow | -0.54 | -6.96 | -12.28 | -12.55 | -61.65 |
| EV to Operating Cash Flow | -0.54 | -6.96 | -12.32 | -12.87 | -64.17 |
| Tangible Book Value Per Share | 14.17 | 1.50 | 2.98 | 4.59 | 6.69 |
| Shareholders’ Equity Per Share | 14.17 | 1.50 | 2.98 | 4.59 | 6.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 4.12 | 0.20 | 0.21 | 0.15 | 0.03 |
| Net Income Per Share | -17.85 | -1.65 | -1.83 | -2.36 | -2.64 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.92 | 0.91 | 0.98 | 1.06 |
| Research & Development to Revenue | 3.71 | 7.47 | 7.81 | 12.76 | 60.04 |
| SG&A to Revenue | 1.79 | 2.40 | 2.86 | 4.00 | 14.60 |
| Stock-Based Compensation to Revenue | 0.36 | 0.96 | 1.17 | 1.67 | 6.75 |
| Income Quality | 1.19 | 0.97 | 1.00 | 0.87 | 0.58 |
Currency in USD
